Tade, Danny Boy L.
HRN: 23-13-05 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/03/2024
ALBENDAZOLE 400MG (TAB)
07/03/2024
08/03/2024
PO
400mg
BID
Neurocystercicosis
Waiting Final Action
Indication: Empiric Type of Infection: Central Nervous System Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes